Clinical Trial Search

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Overall Survival — 32 months

Primary: Progression-free Survival — 25 months

Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants

Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199

Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2

Primary: Median Progression-free Survival — 24.9; 27.3; 26.0 months — p=0.341

Primary: Clinical Response Benefit (Modified Gynecologic Cancer InterGroup [GCIG] Cancer Antigen [CA]-125 Response or Stable Disease) Based on the Response Evaluation Criteria in…

Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants

Primary: Number of Participants With Treatment Success — 23 Participants

Primary: 9-month Progression Rate Post-randomization — 0.386; 0.347; 0.245 Porportion of participants — p=0.065

Primary: Overall Survival — 0.35; 0.34; 0.39; 0.34 Proportion of participants

Primary: Progression-free Survival — 11.0; 12.3; 15.3 months — p=0.448

Primary: PFS — 29.8 Months

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Median Progression-free Survival — 3.2; 4.5 months

Primary: Overall Objective Response — 10; 13; 11; 4 participants

Primary: Objective Response to Treatment With Eribulin Mesylate in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer. — 2; 7; 16; 21 participants

Primary: Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria — 9; 0 participants

Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001

Primary: Overall Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors and by Rustin's Criteria (RECIST) — 4; 5; 9; 4 Participants

Primary: Overall Response Rate (ORR) — 4 participants

Primary: Number of Participants With Drug-related Adverse Events (AEs) of Grade 3 or Higher — 20 Participants

Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…

Primary: Progression-free Survival at 6 Months — 6.5 percentage of participants

Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants

Primary: Percentage of Patients in Remission at 1 Year — 38.1; 38.8 percentage of participants

Primary: Time to Progression (TTP)

Primary: Quality of Life (QOL) Assessed Using Functional Assessment of Cancer Therapy-Ovarian Questionnaire (FACT-O) — 116.32 score on a scale